155 related articles for article (PubMed ID: 37976708)
1. Identification of selective 5-LOX and FLAP inhibitors as novel anti-inflammatory agents by ligand-based virtual screening.
Cerchia C; Küfner L; Werz O; Lavecchia A
Eur J Med Chem; 2024 Jan; 263():115932. PubMed ID: 37976708
[TBL] [Abstract][Full Text] [Related]
2. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
Pergola C; Gerstmeier J; Mönch B; Çalışkan B; Luderer S; Weinigel C; Barz D; Maczewsky J; Pace S; Rossi A; Sautebin L; Banoglu E; Werz O
Br J Pharmacol; 2014 Jun; 171(12):3051-64. PubMed ID: 24641614
[TBL] [Abstract][Full Text] [Related]
3. Novel leukotriene biosynthesis inhibitors (2012-2016) as anti-inflammatory agents.
Werz O; Gerstmeier J; Garscha U
Expert Opin Ther Pat; 2017 May; 27(5):607-620. PubMed ID: 28005436
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E
Cheung SY; Werner M; Esposito L; Troisi F; Cantone V; Liening S; König S; Gerstmeier J; Koeberle A; Bilancia R; Rizza R; Rossi A; Roviezzo F; Temml V; Schuster D; Stuppner H; Schubert-Zsilavecz M; Werz O; Hanke T; Pace S
Eur J Med Chem; 2018 Aug; 156():815-830. PubMed ID: 30053720
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase.
Garscha U; Romp E; Pace S; Rossi A; Temml V; Schuster D; König S; Gerstmeier J; Liening S; Werner M; Atze H; Wittmann S; Weinigel C; Rummler S; Scriba GK; Sautebin L; Werz O
Sci Rep; 2017 Aug; 7(1):9398. PubMed ID: 28839250
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening.
Temml V; Garscha U; Romp E; Schubert G; Gerstmeier J; Kutil Z; Matuszczak B; Waltenberger B; Stuppner H; Werz O; Schuster D
Sci Rep; 2017 Feb; 7():42751. PubMed ID: 28218273
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory celastrol promotes a switch from leukotriene biosynthesis to formation of specialized pro-resolving lipid mediators.
Pace S; Zhang K; Jordan PM; Bilancia R; Wang W; Börner F; Hofstetter RK; Potenza M; Kretzer C; Gerstmeier J; Fischer D; Lorkowski S; Gilbert NC; Newcomer ME; Rossi A; Chen X; Werz O
Pharmacol Res; 2021 May; 167():105556. PubMed ID: 33812006
[TBL] [Abstract][Full Text] [Related]
8. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
Gür ZT; Çalışkan B; Banoglu E
Eur J Med Chem; 2018 Jun; 153():34-48. PubMed ID: 28784429
[TBL] [Abstract][Full Text] [Related]
9. 5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach.
Sinha S; Doble M; Manju SL
Bioorg Med Chem; 2019 Sep; 27(17):3745-3759. PubMed ID: 31331653
[TBL] [Abstract][Full Text] [Related]
10. Differential impact of 5-lipoxygenase-activating protein antagonists on the biosynthesis of leukotrienes and of specialized pro-resolving mediators.
Dahlke P; Peltner LK; Jordan PM; Werz O
Front Pharmacol; 2023; 14():1219160. PubMed ID: 37680719
[TBL] [Abstract][Full Text] [Related]
11. Untangling the web of 5-lipoxygenase-derived products from a molecular and structural perspective: The battle between pro- and anti-inflammatory lipid mediators.
Gilbert NC; Newcomer ME; Werz O
Biochem Pharmacol; 2021 Nov; 193():114759. PubMed ID: 34487716
[TBL] [Abstract][Full Text] [Related]
12. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL
Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibition of human 5-lipoxygenase and microsomal prostaglandin E₂ synthase-1 by the anti-carcinogenic and anti-inflammatory agent embelin.
Schaible AM; Traber H; Temml V; Noha SM; Filosa R; Peduto A; Weinigel C; Barz D; Schuster D; Werz O
Biochem Pharmacol; 2013 Aug; 86(4):476-86. PubMed ID: 23623753
[TBL] [Abstract][Full Text] [Related]
14. Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP).
Ho JD; Lee MR; Rauch CT; Aznavour K; Park JS; Luz JG; Antonysamy S; Condon B; Maletic M; Zhang A; Hickey MJ; Hughes NE; Chandrasekhar S; Sloan AV; Gooding K; Harvey A; Yu XP; Kahl SD; Norman BH
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129800. PubMed ID: 33246032
[TBL] [Abstract][Full Text] [Related]
15. Dual synergistic inhibition of COX and LOX by potential chemicals from Indian daily spices investigated through detailed computational studies.
Rudrapal M; Eltayeb WA; Rakshit G; El-Arabey AA; Khan J; Aldosari SM; Alshehri B; Abdalla M
Sci Rep; 2023 May; 13(1):8656. PubMed ID: 37244921
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors by Exploiting a Multistep Virtual Screening Protocol.
Olgac A; Carotti A; Kretzer C; Zergiebel S; Seeling A; Garscha U; Werz O; Macchiarulo A; Banoglu E
J Chem Inf Model; 2020 Mar; 60(3):1737-1748. PubMed ID: 32045233
[TBL] [Abstract][Full Text] [Related]
17. Rotational constriction of curcuminoids impacts 5-lipoxygenase and mPGES-1 inhibition and evokes a lipid mediator class switch in macrophages.
Rao Z; Caprioglio D; Gollowitzer A; Kretzer C; Imperio D; Collado JA; Waltl L; Lackner S; Appendino G; Muñoz E; Temml V; Werz O; Minassi A; Koeberle A
Biochem Pharmacol; 2022 Sep; 203():115202. PubMed ID: 35932797
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis.
Bäck M
Curr Pharm Des; 2009; 15(27):3116-32. PubMed ID: 19754386
[TBL] [Abstract][Full Text] [Related]
19. Novel benzoxanthene lignans that favorably modulate lipid mediator biosynthesis: A promising pharmacological strategy for anti-inflammatory therapy.
Gerstmeier J; Kretzer C; Di Micco S; Miek L; Butschek H; Cantone V; Bilancia R; Rizza R; Troisi F; Cardullo N; Tringali C; Ialenti A; Rossi A; Bifulco G; Werz O; Pace S
Biochem Pharmacol; 2019 Jul; 165():263-274. PubMed ID: 30836057
[TBL] [Abstract][Full Text] [Related]
20. Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR.
Meshram MA; Bhise UO; Makhal PN; Kaki VR
Eur J Med Chem; 2021 Dec; 225():113804. PubMed ID: 34479036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
